Latest & greatest articles for insulin

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on insulin or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on insulin and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for insulin

761. Twice daily versus four times daily insulin dose regimens for diabetes in pregnancy: randomised controlled trial. Full Text available with Trip Pro

Twice daily versus four times daily insulin dose regimens for diabetes in pregnancy: randomised controlled trial. To compare perinatal outcome and glycaemic control in two groups of pregnant diabetic patients receiving two insulin regimens.Randomised controlled open label study.University affiliated hospital, Israel.138 patients with gestational diabetes mellitus and 58 patients with pregestational diabetes mellitus received insulin four times daily, and 136 patients with gestational diabetes (...) and 60 patients with pregestational diabetes received insulin twice daily.Three doses of regular insulin before meals and an intermediate insulin dose before bedtime (four times daily regimen), and a combination of regular and intermediate insulin in the morning and evening (twice daily regimen).Maternal glycaemic control and perinatal outcome.Mean daily insulin concentration before birth was higher in the women receiving insulin four times daily compared with twice daily: by 22 units (95% confidence

1999 BMJ Controlled trial quality: predicted high

762. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. (Abstract)

Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. Treatment with diet alone, insulin, sulfonylurea, or metformin is known to improve glycemia in patients with type 2 diabetes mellitus, but which treatment most frequently attains target fasting plasma glucose (FPG) concentration of less than 7.8 mmol/L (140 mg/dL) or glycosylated (...) a median (interquartile range) FPG concentration of 11.5 (9.0-14.4) mmol/L [207 (162-259) mg/dL], HbA1c levels of 9.1% (7.5%-10.7%), and a mean (SD) body mass index of 29 (6) kg/m2.After 3 months on a low-fat, high-carbohydrate, high-fiber diet, patients were randomized to therapy with diet alone, insulin, sulfonylurea, or metformin.Fasting plasma glucose and HbA1c levels, and the proportion of patients who achieved target levels below 7% HbA1c or less than 7.8 mmol/L (140 mg/dL) FPG at 3, 6, or 9

1999 JAMA Controlled trial quality: uncertain

763. Insulin lispro: a critical evaluation

Insulin lispro: a critical evaluation Insulin lispro: a critical evaluation Insulin lispro: a critical evaluation Shukla VK, Otten N Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Shukla VK, Otten N. Insulin lispro: a critical evaluation. Ottawa: Canadian Coordinating Office for Health Technology Assessment (CCOHTA). Technology Report (...) Issue 5. 1999 Authors' objectives To summarise the evidence relating to the effectiveness and cost effectiveness of insulin lispro. Authors' conclusions The reported advantages of lispro are: It lessens the rise in serum glucose after meals. Hypoglycemic episodes occur less frequently. The overall glycemic control is improved in patients with type I diabetes who require insulin pumps. It has been proposed that lispro would be of benefit to patients with unpredictable mealtimes to allow more schedule

1999 Health Technology Assessment (HTA) Database.

764. Improvement of insulin sensitivity by short-term exercise training in hypertensive African American women. (Abstract)

Improvement of insulin sensitivity by short-term exercise training in hypertensive African American women. African American women have a high prevalence of insulin resistance, non-insulin-dependent diabetes mellitus, obesity, and hypertension that may be linked to low levels of physical activity. We sought to determine whether 7 days of aerobic exercise improved glucose and insulin metabolism in 12 obese (body fat >35%), hypertensive (systolic blood pressure > or =140 and/or diastolic blood (...) pressure > or =90 mmHg) African American women (mean age 51+/-8 years). Insulin-assisted frequently-sampled intravenous glucose tolerance tests were performed at baseline and 14 to 18 hours after the 7th exercise session. There was no significant change in maximal oxygen consumption, body composition, or body weight after the 7 days of aerobic exercise. The insulin sensitivity index increased (2.68+/-0.45 x 10[-5] to 4.23+/-0.10 x 10[-5] [min(-1)/pmol/L], P=.02). Fasting (73+/-9 to 50+/-9 pmol/L, P=.02

1998 Hypertension (Dallas, Tex. : 1979)

765. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. (Abstract)

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Improved blood-glucose control decreases the progression of diabetic microvascular disease, but the effect on macrovascular complications is unknown. There is concern that sulphonylureas may increase cardiovascular mortality in patients with type 2 diabetes and that high insulin (...) concentrations may enhance atheroma formation. We compared the effects of intensive blood-glucose control with either sulphonylurea or insulin and conventional treatment on the risk of microvascular and macrovascular complications in patients with type 2 diabetes in a randomised controlled trial.3867 newly diagnosed patients with type 2 diabetes, median age 54 years (IQR 48-60 years), who after 3 months' diet treatment had a mean of two fasting plasma glucose (FPG) concentrations of 6.1-15.0 mmol/L were

1998 Lancet Controlled trial quality: predicted high

766. Effect of troglitazone in insulin-treated patients with type II diabetes mellitus. Troglitazone and Exogenous Insulin Study Group. (Abstract)

Effect of troglitazone in insulin-treated patients with type II diabetes mellitus. Troglitazone and Exogenous Insulin Study Group. Troglitazone is a new oral antidiabetic drug that increases the sensitivity of peripheral tissues to insulin. It may therefore increase the efficacy of exogenous insulin in patients with insulin-resistant diabetes mellitus.We studied the effect of troglitazone or placebo in 350 patients with poorly controlled non-insulin-dependent (type 2) diabetes mellitus (...) (glycosylated hemoglobin values, 8 to 12 percent; normal, 4.3 to 6.1 percent) despite therapy with at least 30 U of insulin daily. The patients were randomly assigned to receive 200 mg of troglitazone (116 patients), 600 mg of troglitazone (116 patients), or placebo (118 patients) daily for 26 weeks. Insulin doses were not increased and were reduced only to prevent hypoglycemia. Glycosylated hemoglobin, serum glucose while fasting, serum total cholesterol, high-density lipoprotein cholesterol, low-density

1998 NEJM Controlled trial quality: uncertain

767. Effect of lisinopril on progression of retinopathy in normotensive people with type 1 diabetes. The EUCLID Study Group. EURODIAB Controlled Trial of Lisinopril in Insulin-Dependent Diabetes Mellitus. (Abstract)

Effect of lisinopril on progression of retinopathy in normotensive people with type 1 diabetes. The EUCLID Study Group. EURODIAB Controlled Trial of Lisinopril in Insulin-Dependent Diabetes Mellitus. Retinopathy commonly occurs in people with type 1 diabetes. Strict glycaemic control can decrease development and progression of retinopathy only partially. Blood pressure is also a risk factor for microvascular complications. Antihypertensive therapy, especially with inhibitors of angiotensin

1998 Lancet Controlled trial quality: predicted high

768. The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. (Abstract)

The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. It has recently been reported that the use of calcium-channel blockers for hypertension may be associated with an increased risk of cardiovascular complications. Because this issue remains controversial, we studied the incidence of such complications in patients with non-insulin-dependent diabetes mellitus and hypertension who were randomly assigned

1998 NEJM Controlled trial quality: uncertain

769. Meta-analysis of the effect of insulin lispro on severe hypoglycemia in patients with type 1 diabetes

Meta-analysis of the effect of insulin lispro on severe hypoglycemia in patients with type 1 diabetes Meta-analysis of the effect of insulin lispro on severe hypoglycemia in patients with type 1 diabetes Meta-analysis of the effect of insulin lispro on severe hypoglycemia in patients with type 1 diabetes Brunelle R L, Llewelyn J, Anderson J H, Gale E A, Koivisto V A Authors' objectives To compare the frequency of severe hypoglycaemia during insulin lispro and human regular insulin in type 1 (...) diabetic patients. Searching The Eli Lilly database was searched. Study selection Study designs of evaluations included in the review Randomised controlled trials (RCTs) comparing the incidence of severe hypoglycaemia in type 1 diabetics during insulin lispro therapy and during soluble insulin therapy. The trials were included if they measured hypoglycaemia using a standard hypoglycaemia questionnaire, they enrolled at least 50 patients, and were of at least 2 months' duration. Both parallel

1998 DARE.

770. Routine treatment of insulin-dependent diabetic patients with ACE inhibitors to prevent renal failure: an economic evaluation

Routine treatment of insulin-dependent diabetic patients with ACE inhibitors to prevent renal failure: an economic evaluation Routine treatment of insulin-dependent diabetic patients with ACE inhibitors to prevent renal failure: an economic evaluation Routine treatment of insulin-dependent diabetic patients with ACE inhibitors to prevent renal failure: an economic evaluation Kiberd B A, Jindal K K Record Status This is a critical abstract of an economic evaluation that meets the criteria (...) for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Screening for microalbuminuria, hypertension and macroproteinuria and routine treatment of insulin-dependent diabetic patients (IDDM) with angiotensin-converting enzymes (ACEs). The treatment with ACE inhibition is equivalent to captopril 25 mg three times a day. If two of three

1998 NHS Economic Evaluation Database.

771. Initiating insulin treatment in insulin-requiring type 2 diabetic patients: comparative efficiency and cost of outpatient and inpatient management

Initiating insulin treatment in insulin-requiring type 2 diabetic patients: comparative efficiency and cost of outpatient and inpatient management Initiating insulin treatment in insulin-requiring type 2 diabetic patients: comparative efficiency and cost of outpatient and inpatient management Initiating insulin treatment in insulin-requiring type 2 diabetic patients: comparative efficiency and cost of outpatient and inpatient management Penfornis A, Millot L Record Status This is a critical (...) abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Outpatient approach to initiating insulin therapy in insulin-requiring Type 2 diabetic patients. Type of intervention Treatment. Economic study type Cost-effectiveness analysis. Study population Type 2 diabetic patients

1998 NHS Economic Evaluation Database.

772. Cost-effectiveness of the primary prevention of non-insulin dependent diabetes mellitus

Cost-effectiveness of the primary prevention of non-insulin dependent diabetes mellitus Cost-effectiveness of the primary prevention of non-insulin dependent diabetes mellitus Cost-effectiveness of the primary prevention of non-insulin dependent diabetes mellitus Segal L, Dalton A C, Richardson J Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions (...) followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Programmes for the primary prevention of non-insulin dependent diabetes mellitus (NIDDM). Type of intervention Primary prevention. Economic study type Cost-effectiveness analysis. Study population The study targeted selected groups including persons with IGT, overweightese men, seriously obese persons, women with previous gestational diabetes and the general population. Setting

1998 NHS Economic Evaluation Database.

773. Pancreatic transplantation in insulin-dependent diabetes

Pancreatic transplantation in insulin-dependent diabetes Pancreatic transplantation in insulin-dependent diabetes Pancreatic transplantation in insulin-dependent diabetes Scottish Health Purchasing Information Centre Record Status This is a bibliographic record of a published health technology assessment. The agency responsible for the publication, formerly a member of INAHTA, has subsequently been disbanded. No evaluation of the quality of this assessment has been made for the HTA database (...) . Citation Scottish Health Purchasing Information Centre. Pancreatic transplantation in insulin-dependent diabetes. Aberdeen: Scottish Health Purchasing Information Centre (SHPIC) 1998: 12 Authors' objectives This report aims to answer the following questions: 1. Is pancreatic transplantation worth doing as an addition to renal transplantation alone? Are the benefits in terms of independence from insulin injections, improved diabetic control, and reduced long-term complications, sufficient to justify

1998 Health Technology Assessment (HTA) Database.

774. Economic evaluation of insulin lispro versus neutral (regular) insulin therapy using a willingness to pay approach

Economic evaluation of insulin lispro versus neutral (regular) insulin therapy using a willingness to pay approach Economic evaluation of insulin lispro versus neutral (regular) insulin therapy using a willingness to pay approach Economic evaluation of insulin lispro versus neutral (regular) insulin therapy using a willingness to pay approach Davey P, Grainger D, MacMillan J, Rajan N, Aristides M, Dobson M Record Status This is a critical abstract of an economic evaluation that meets (...) the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The study investigated the use of insulin lispro, a new insulin at the time of study, in the treatment of diabetes mellitus. Insulin lispro (Humalog(R)), an analogue of human insulin, is a new biosynthetic insulin analogue created by reversing the amino acids

1998 NHS Economic Evaluation Database.

775. Treatment strategies for insulin-dependent diabetics with ESRD: a cost-effectiveness decision analysis model

Treatment strategies for insulin-dependent diabetics with ESRD: a cost-effectiveness decision analysis model Treatment strategies for insulin-dependent diabetics with ESRD: a cost-effectiveness decision analysis model Treatment strategies for insulin-dependent diabetics with ESRD: a cost-effectiveness decision analysis model Douzdjian V, Ferrara D, Silvestri G Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract (...) to consider 5 scenarios: (1) death from operation or complications, (2) kidney fails/pancreas works, (3) pancreas fails/ kidney works, (4) both organs fail, and (5) both organs work. In this analysis, preferences elicited for states from best to worst (1 - 0) were estimated as: 1 - dialysis free, insulin free, 0.6 - dialysis free, insulin dependent, 0.5 - dialysis dependent, insulin free, 0.4 dialysis dependent, insulin dependent, 0.0 - and death. Direct costs The costs of diabetes management, dialysis

1998 NHS Economic Evaluation Database.

776. [Medication consumption in diabetes mellitus (VI): economics and effectiveness of insulin and sulfonylurea combination therapy compared with conventional two daily doses]

[Medication consumption in diabetes mellitus (VI): economics and effectiveness of insulin and sulfonylurea combination therapy compared with conventional two daily doses] Consumo de medicacion en la diabetes mellitus (VI): economia y efectividad de la terapia combinada con insulina y sulfonilureas sobre la administracion convencional con dos dosis [Medication consumption in diabetes mellitus (VI): economics and effectiveness of insulin and sulfonylurea combination therapy compared (...) with conventional two daily doses] Consumo de medicacion en la diabetes mellitus (VI): economia y efectividad de la terapia combinada con insulina y sulfonilureas sobre la administracion convencional con dos dosis [Medication consumption in diabetes mellitus (VI): economics and effectiveness of insulin and sulfonylurea combination therapy compared with conventional two daily doses] Costa B, Estopa A, Borras J, Sabate A Record Status This is a critical abstract of an economic evaluation that meets the criteria

1998 NHS Economic Evaluation Database.

777. Prospective randomised study of intensive insulin treatment on long term survival after acute myocardial infarction in patients with diabetes mellitus. DIGAMI (Diabetes Mellitus, Insulin Glucose Infusion in Acute Myocardial Infarction) Study Group. Full Text available with Trip Pro

Prospective randomised study of intensive insulin treatment on long term survival after acute myocardial infarction in patients with diabetes mellitus. DIGAMI (Diabetes Mellitus, Insulin Glucose Infusion in Acute Myocardial Infarction) Study Group. To test the hypothesis that intensive metabolic treatment with insulin-glucose infusion followed by multidose insulin treatment in patients with diabetes mellitus and acute myocardial infarction improves the prognosis.Patients with diabetes mellitus (...) and acute myocardial infarction were randomly allocated standard treatment plus insulin-glucose infusion for at least 24 hours followed by multidose insulin treatment or standard treatment (controls).620 patients were recruited, of whom 306 received intensive insulin treatment and 314 served as controls.Long term all cause mortality.The mean (range) follow up was 3.4 (1.6-5.6) years. There were 102 (33%) deaths in the treatment group compared with 138 (44%) deaths in the control group (relative risk (95

1997 BMJ Controlled trial quality: uncertain

778. Randomised placebo-controlled trial of lisinopril in normotensive patients with insulin-dependent diabetes and normoalbuminuria or microalbuminuria. The EUCLID Study Group. (Abstract)

Randomised placebo-controlled trial of lisinopril in normotensive patients with insulin-dependent diabetes and normoalbuminuria or microalbuminuria. The EUCLID Study Group. Renal disease in people with insulin-dependent diabetes (IDDM) continues to pose a major health threat. Inhibitors of angiotensin-converting enzyme (ACE) slow the decline of renal function in advanced renal disease, but their effects at earlier stages are unclear, and the degree of albuminuria at which treatment should start

1997 Lancet Controlled trial quality: predicted high

779. Randomised placebo-controlled trial of human recombinant insulin-like growth factor I plus intensive insulin therapy in adolescents with insulin-dependent diabetes mellitus. (Abstract)

Randomised placebo-controlled trial of human recombinant insulin-like growth factor I plus intensive insulin therapy in adolescents with insulin-dependent diabetes mellitus. Good glycaemic control in insulin-dependent diabetes mellitus (IDDM) to prevent complications may be difficult to achieve during adolescence, because abnormalities in production of growth hormone or insulin-like growth-factor-I (IGF-I) can lead to lower insulin sensitivity. Recombinant human IGF-I (rhIGF-I) given (...) as an adjunct to insulin therapy in IDDM, might improve glycaemic control in adolescents; we investigated the effects of the addition of IGF-I in a randomised, double-blind, placebo-controlled trial.53 patients with IDDM (26 male, 27 female) with a median age of 16.1 years (range 10.8-20.6) and diabetes of more than 2 years' duration were randomly assigned subcutaneous rhIGF-I (20 or 40 microg/kg daily [n=18, n=18, respectively]) or placebo (n=17), both in addition to multiple-injection insulin therapy

1997 Lancet Controlled trial quality: predicted high

780. Clinical outcomes with insulin lispro compared with human regular insulin: a meta-analysis

Clinical outcomes with insulin lispro compared with human regular insulin: a meta-analysis Clinical outcomes with insulin lispro compared with human regular insulin: a meta-analysis Clinical outcomes with insulin lispro compared with human regular insulin: a meta-analysis Davey P, Grainger D, MacMillan J, Rajan N, Aristides M, Gliksman M Authors' objectives To compare insulin lispro and human regular insulin across a range of outcomes common in modern diabetes management, to establish a basis (...) for subsequent economic evaluation. Searching Reports of all phase III trials conducted by Eli Lily and Company were obtained from the New Drug Application package. MEDLINE via SilverPlatter was searched using the following keywords: 'Lys Pro' or 'lispro', 'lyspro', 'LY 275585', 'LY-275585', 'Humulin R', 'Humulin regular', 'Humulin (short acting or short-acting)', 'insulin regular', and 'Actrapid'. Dial-up searches of MEDLINE (from 1966 to 1996) and EMBASE (from 1974 to 1996) were conducted using similar

1997 DARE.